Schering Plough News

The new Merck & Co. becomes the world's second-biggest drugmaker overnight, and it's boasting a fat wallet to fund future deals.

What's the only thing more embarrassing for a drugmaker than getting a "complete response letter" for a New Drug Application from the Food and Drug Administration? Having the FDA refuse to file its NDA in the first place.

KXNet.com North Dakota News _title> _head> _script> _script> JavaScript DHTML Dro0 Down Men5 By Milonic _a> _div> Merck, now No.

Schering-Plough Corporation today reported two data presentations supporting response guided therapy with boceprevir combination therapy in patients with chronic hepatitis C virus genotype 1. These retrospective analyses were presented at the American Association for the Study of Liver Diseases Annual Meeting in Boston, Oct.

Schering-Plough Corporation announced that its investigational sublingual Grass Allergy Immunotherapy Tablet has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma.

The new Merck & Co . has become the world's second-biggest drugmaker overnight with a huge acquisition, but it still has a fat wallet and plans more wheeling and dealing.

Technically, Schering lives on as a quirk; It was a reverse merger , after all. But after Schering bought Merck As "Merck," it answers the call.

Merck disclosed the rare move by the Food and Drug Administration in a regulatory filing Monday.

Enzon Inc. filed Quarterly Report for the period ended 2009-09-30. Enzon Pharmaceuticals Inc.

Schering-Plough Corp. announced today the U.S. Food and Drug Administration has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRONA for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

KENILWORTH,A N.J. The Food and Drug Administration has rejected an approval application for an additional use for a hepatitis C drug.

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir , an Investigational, Once-Daily Protease Inhibitor for Hepatitis C Interim results of Phase IIa NEXT-I study presented at American Association for the Study of Liver Diseases Annual Meeting BOSTON, Nov.

Schering-Plough Corporation today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs.

U.S. regulators won't accept drugmaker Merck's application for a new combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug.

Schering-Plough Corp. said its experimental hepatitis C drug boceprevir helped eliminate the virus in about half of patients who did not respond to standard treatments.

More than 80% of hepatitis C patients were cured after treatment with a new twice-daily dose of the experimental drug telaprevir made by Vertex Pharmaceuticals , according to data from a phase II study released Saturday.

Schering-Plough Corp. announced today the U.S. Food and Drug Administration has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRONA for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

Merck & Co., Inc. must sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and Schering-Plough must sell its assets related to significant drugs for nausea and vomiting in humans, in order for Schering-Plough to complete its proposed $41.1 billion acquisition of Merck, the Federal Trade Commission announced ...

Merck & Co. and Schering-Plough Corp. said Thursday they have won merger approval from the Federal Trade Commission and antitrust regulators in Switzerland and Canada.

Standard & Poor's said Thursday it will add miner Freeport-McMoRan Copper & Gold Inc.